ST
SCMP

Spot Trading’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Spot Trading’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,950
Closed -$43K – 5009
2014
Q1 		$43K Buy
+5,950
New +$50.9K ﹤0.01% 3683

Other funds holding SCMP

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Spot Trading's SCMP Position: Q2 2014 in Review

Spot Trading sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2014, closing a stake of 5,950 shares — an estimated $43K sold.

Spot Trading first reported a position in SCMP in Q1 2014 and held it in 1 quarter. The position peaked at $43K in Q1 2014. 71 funds tracked by Wall St. Rank hold SCMP as of Q2 2014.

  • Spot Trading reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Spot Trading sold 5,950 Sucampo Pharmaceuticals, Inc. shares in Q2 2014, an estimated $43K.
  • Spot Trading first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Spot Trading's Sucampo Pharmaceuticals, Inc. position peaked at $43K in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2014.

Based on Spot Trading's 13F filing for Q2 2014, filed 12 Aug 2014.